Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma PDF Print E-mail
Thursday, 11 February 2010 11:22
Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma.  Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

"Our data shows that in mice deficient for the LPA1 receptor, there is dramatic protection from the bleomycin-induced skin fibrosis seen in normal mice," said Dr. Tager, a member of Amira's Scientific Advisory Board.  "In addition, similar protection from fibrosis was observed in normal mice treated with Amira's LPA1 receptor antagonist, AM095."

Peppi Prasit, Ph.D., Chief Scientific Officer, said, "AM095 is an orally available, potent and selective antagonist of the LPA1 receptor.  We are currently moving AM095 and AM152, another LPA1 antagonist, through GLP toxicology testing and expect to initiate human clinical studies in the second half of 2010."

Bob Baltera, Chief Executive Officer, added, "So far we have seen compelling data in numerous preclinical models of fibrosis.  We are excited by the possibility of eventually exploring efficacy in human disease settings, such as idiopathic pulmonary fibrosis, scleroderma, kidney and liver fibrosis, and various metastatic cancers. There is a lot of work to be done, and we are up to the challenge."

Source: Amira Pharmaceuticals
 
More articles :

» DETECT Algorithm Increases Rate Of Diagnosis For PAH In Scleroderma Patients

The use of a two-step algorithm significantly increased the rate at which pulmonary arterial hypertension was diagnosed in patients with in a prospective, observational, cross-sectional study. The results of the , presented at the annual European...

» Quality Indicator Sets For Scleroderma

Despite the increasing awareness of Scleroderma (SSc), it continues to have a detrimental effect of the quality of health and lives of those with it. The medical community has recognized that although early treatment of can have a substantial...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Interleukin-6: A New Therapeutic Target in Scleroderma

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells,...

» UTHealth Uses $1.9 million Grant To Study Therapy For Autoimmunity

A researcher at (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.The preclinical study, funded with a $1.9 million grant...

» Long-Term Outcomes of Scleroderma Renal Crisis

In a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by...